Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Nov 4;99(9):1380-2.
doi: 10.1038/sj.bjc.6604709. Epub 2008 Oct 7.

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib

B Billemont  1 , J Medioni, L Taillade, D Helley, J B Meric, O Rixe, S Oudard
Affiliations

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib

B Billemont et al. Br J Cancer. .

Abstract

Sunitinib, a multitargeted tyrosine-kinase inhibitor, extends survival of patients with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumours. Between October 2005 and March 2007, we retrospectively reviewed blood glucose level variations associated with sunitinib therapy in patients treated for mRCC. Nineteen of the patients had type II diabetes. All 19 patients had a decrease in blood glucose level (mean 1.77 mmol l(-1)) after 4 weeks of treatment. This was followed by re-elevation in the 2-week rest period. After two cycles of sunitinib administration, two patients had stopped blood glucose-lowering drugs whereas five other patients had normalised their blood glucose level. On the basis of pre-clinical data, we hypothesise that several mechanisms could be involved in this process, such as capillary regression of pancreatic islets, IGF-1 modulation through HIF1-alpha or NF-kappaB activation. In addition, a decrease of glucose uptake in the context of concomitant gastrointestinal toxicity cannot be excluded. Glycaemic control should be carefully evaluated in diabetic patients treated with sunitinib, and routine monitoring is warranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean blood glucose levels in 19 type II diabetic patients and 9 non-diabetic patients during sunitinib treatment for mRCC.
See this image and copyright information in PMC

References

    1. Carroll VA, Ashcroft M (2006) Role of hypoxia-inducible factor (HIF)-1alpha vs HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von hippel-lindau function: implications for targeting the HIF pathway. Cancer Res 12: 6264–6270 - PubMed
    1. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 9: 734–745 - PubMed
    1. Gillessen S, Graf L, Korte W, Cerny T (2007) Macrocytosis and cobalamin deficiency in patients treated with sunitinib. N Engl J Med 356(22): 2330–2331 - PubMed
    1. Hagerkvist R, Sandler S, Mokhtari D, Welsh N (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 21: 618–628 - PubMed
    1. Hamberg P, de Jong FA, Boonstra JG, van Doorn J, Verweij J, Sleijfer S (2006) Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol 24(18): e30–e31 - PubMed

MeSH terms